Hetero announced this week the launch in India of its adalimumab biosimilar, marketed under the brand name Mabura. Mabura is a biosimilar of AbbVie’s Humira and is indicated for the treatment of rheumatoid arthritis and other auto-immune disorders. According to the company, Mabura is Hetero’s fourth biosimilar product. Glenmark also announced this…